Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.07 USD | +6.58% | -28.57% | -12.71% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.71% | 244M | |
+12.76% | 227B | |
+13.56% | 192B | |
+17.33% | 136B | |
+28.52% | 108B | |
+1.67% | 64.07B | |
+17.48% | 52.1B | |
+7.04% | 51.87B | |
+10.47% | 44.33B | |
+5.39% | 36.75B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wolfe Research Starts NeuroPace at Outperform With $13 Price Target